The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Off-label use of fam-trastuzumab deruxtecan in desmoplastic small round cell tumor.
 
Emily Slotkin
Consulting or Advisory Role - Guidepoint Global; Inhibrx
Research Funding - Esperas Pharma; Lilly (Inst); Lilly (Inst)
 
Tamar Feinberg
No Relationships to Disclose
 
Umesh Bhanot
No Relationships to Disclose
 
Anita Price
No Relationships to Disclose
 
Gerald Behr
No Relationships to Disclose
 
Neeta Pandit-Taskar
Honoraria - Actinium Pharmaceuticals
Consulting or Advisory Role - Actinium Pharmaceuticals; Regeneron; Telix Pharmaceuticals
Speakers' Bureau - Telix Pharmaceuticals
Research Funding - Bayer Health (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Fusion Pharmaceuticals (Inst); Imaginab (Inst); Janssen (Inst); Regeneron (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Actinium Pharmaceuticals; Bayer
 
Narasimhan Agaram
No Relationships to Disclose
 
Cristina Antonescu
No Relationships to Disclose
 
Meera Hameed
No Relationships to Disclose
 
Konstantinos Linos
No Relationships to Disclose
 
Carla Saoud
No Relationships to Disclose
 
Dylan Domenico
No Relationships to Disclose
 
Elli Papaemmanuil
Leadership - Isabl Technologies
Stock and Other Ownership Interests - Isabl Technologies; TenSixteen Bio
Honoraria - Celgene; Novartis
Consulting or Advisory Role - TenSixteen Bio
Speakers' Bureau - Illumina
Research Funding - Celgene
Travel, Accommodations, Expenses - Celgene; Illumina; Novartis
 
Filemon Dela Cruz
Research Funding - Eisai; Y-mAbs Therapeutics
 
Chelsey Burke
No Relationships to Disclose
 
Michael Ortiz
No Relationships to Disclose
 
Julia Glade Bender
Consulting or Advisory Role - Jazz Pharmaceuticals
Research Funding - Bayer (Inst); Eisai (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on a T lympboblastic lymphoma cell line, CUTLL1
Travel, Accommodations, Expenses - Amgen (Inst); Eisai (Inst)
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Eisai; Merck; Pfizer; SpringWorks Therapeutics
 
Andrew Kung
Leadership - Isabl Technologies
Stock and Other Ownership Interests - Isabl Technologies
Consulting or Advisory Role - DarwinHealth; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Licensing and royalty from bioluminescence imaging models; Licensing of technologies for cancer whole genome and transcriptome sequencing
 
Damon Reed
Consulting or Advisory Role - Eisai; SpringWorks Therapeutics